Article Text

PDF

Pulmonary arterial hypertension
P30 The changing face of pulmonary hypertension: the role of heart and lung disease
  1. SF Crawley,
  2. MK Johnson,
  3. AJ Peacock
  1. Scottish Pulmonary Vascular Unit (SPVU), Glasgow, UK

Abstract

Introduction The advent of disease-targeted therapy for pulmonary arterial hypertension (PAH) has led to an increased awareness of this condition within the general cardiology and respiratory communities. More patients are being referred to specialist centres for diagnostic assessment, however there is concern that many will have pulmonary hypertension (PH) due to underlying lung disease or left heart disease.

Aim The aim of the study was to review the outcome of diagnostic admissions to the Scottish Pulmonary Vascular Unit (SPVU) before (2003–2005) and after (2006–2009) the introduction of disease-targeted PAH therapy.

470 new patients with suspected PH were admitted between January 2003 and December 2009 for diagnostic assessment including right heart catheterisation (RHC). Demographic and haemodynamic data from these patients were retrospectively reviewed. Following RHC patients were diagnosed with:

  • – Group 1. PAH;

  • – Group 2. Pulmonary venous hypertension (PVH) due to left heart disease;

  • – Group 3. PH due to hypoxic lung disease (HLDPH);

  • – Group 4. Chronic thromboembolic PH (CTEPH);

  • – Group 5. PH due to unclear multifactorial mechanisms (PH Misc);

  • – No PH.

Results In 2003–2005, 114 patients underwent diagnostic assessment, and 112 had PH. Of these 77.7% had PAH and 18.8% had CTEPH. Only 2.7% of patients had PVH and 0.8% had HLDPH. In 2006–2009, 356 patients underwent diagnostic assessment, and 308 had PH. Of these only 51.9% had PAH and 15.9% had CTEPH. However, now 17.9% of patients had PVH, and 10.4% had HLDPH. 48 patients had No PH at the time of RHC (Abstract P30 Figure 1).

Abstract P30 Figure 1

Outcome of diagnostic assessment in the pre and post-treatment era.

Conclusion Prior to admission all referrals are screened by an SPVU consultant, but despite this there are a significant number of patients proceeding to RHC who will have PH due to left heart or lung disease. This highlights the importance of fully assessing all patients with suspected PH, as per ESC/ERS 2009 guidelines, before instituting expensive and potentially dangerous PAH therapy. We need to improve our non-invasive screening methods so that fewer patients proceed to RHC who do not have PAH.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.